English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Prostate cancer ( PC a) death primarily occurs due to metastasis of the cells, but little is known about the underlying molecular mechanisms. This study aimed to evaluate the expression of   UNC 5D , a newly identified tumor suppressor gene, analyze its epigenetic alterations, and elucidate its functional relevance to  PC a metastasis. Meta‐analysis of publicly available microarray datasets revealed that   UNC 5D  expression was frequently downregulated in  PC a tissues and inversely associated with  PC a metastasis. These results were verified in clinical specimens by real‐time  PCR  and immunohistochemistry assays. Through methylation analysis, the downregulated expression of   UNC 5D  in  PC a tissues and cell lines was found to be attributable to the hypermethylation of the promoter. A negative correlation was observed between methylation and   UNC 5D   mRNA  expression in  PC a samples. The ectopic expression of   UNC 5D  in  PC a cells effectively reduced their ability to migrate and invade both in vitro and in vivo, and si RNA ‐mediated knockdown of   UNC 5D  yielded consistent results.   UNC 5D  can recruit and activate death‐associated protein kinase 1, which remained to be essential for its metastatic suppressor function. In conclusion, these results suggested that   UNC 5D  as a novel putative metastatic suppressor gene that is commonly down‐regulated by hypermethylation in  PC a.

UNC5D , suppressed by promoter hypermethylation, inhibits cell metastasis by activating death‐associated protein kinase 1 in prostate cancer